Markers of Resistance to anti-EGFR Therapy in Colorectal Cancer
作者： Walid Shaib , Reena Mahajan , Bassel El-Rayes
DOI: 10.3978/J.ISSN.2078-6891.2013.029
关键词: Bioinformatics 、 Colorectal cancer 、 KRAS 、 EGFR inhibitors 、 Mechanism (biology) 、 Ligand (biochemistry) 、 Cancer research 、 Epidermal growth factor receptor 、 Activating mutation 、 Medicine 、 Signal transduction
摘要: Epidermal growth factor receptor (EGFR) is a therapeutic target in colorectal cancer (CRC). The benefit from EGFR inhibitors appears to be limited subset of patients with CRC. Mechanisms resistance are being identified. KRAS codon 12 activating mutation predominate mechanism around 40% advanced Other potential mechanisms include ligand expression, increased number, mutations BRAF and activation alternate signaling pathways.
amegroups.com参考文章(76)
David Solit, Neal Rosen, Oncogenic RAF: a brief history of time. Pigment Cell & Melanoma Research. ,vol. 23, pp. 760- 762 ,(2010) , 10.1111/J.1755-148X.2010.00779.X
Gabriel Capellà, Lourdes Farré, Isolda Casanova, Adela Mazo, Sílvia Guerrero, Ramon Mangues, K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Research. ,vol. 60, pp. 6750- 6756 ,(2000)
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
J Souglakos, J Philips, R Wang, S Marwah, M Silver, M Tzardi, J Silver, S Ogino, S Hooshmand, E Kwak, E Freed, J A Meyerhardt, Z Saridaki, V Georgoulias, D Finkelstein, C S Fuchs, M H Kulke, R A Shivdasani, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. British Journal of Cancer. ,vol. 101, pp. 465- 472 ,(2009) , 10.1038/SJ.BJC.6605164
Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata-Ford, John R. Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar, Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab JAMA. ,vol. 304, pp. 1812- 1820 ,(2010) , 10.1001/JAMA.2010.1535
Elizabeth Buck, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, Stuart Thomson, Mark Mulvihill, Sharon Barr, Eric Brown, Mathew O'Connor, Yan Yao, Jonathan Pachter, Mark Miglarese, David Epstein, Kenneth K. Iwata, John D. Haley, Neil W. Gibson, Qun-Sheng Ji, Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Research. ,vol. 68, pp. 8322- 8332 ,(2008) , 10.1158/0008-5472.CAN-07-6720
Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, An Capoen, Maria Debiec-Rychter, Jean-Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study Clinical Cancer Research. ,vol. 14, pp. 5869- 5876 ,(2008) , 10.1158/1078-0432.CCR-08-0449
Zheng Jiang, Chunxiang Li, Fuyuan Li, Xishan Wang, EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis PLoS ONE. ,vol. 8, pp. e56205- ,(2013) , 10.1371/JOURNAL.PONE.0056205
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
L. Zhao, P. K. Vogt, Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 2652- 2657 ,(2008) , 10.1073/PNAS.0712169105